Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias
about
Tolvaptan: the evidence for its therapeutic value in acute heart failure syndromeTolvaptan, hyponatremia, and heart failure.Risk assessment of mechanism-based inactivation in drug-drug interactions.Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.V2 receptor antagonism with tolvaptan in heart failure.Role of tolvaptan in acute decompensated heart failure.Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).Tolvaptan for the treatment of heart failure: a review of the literature.Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.Update on tolvaptan for the treatment of hyponatremia.Vaptans: A new option in the management of hyponatremia.Tolvaptan for the treatment of hyponatremia and congestive heart failure.Tolvaptan and its potential in the treatment of hyponatremia.Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process.
P2860
Q33973976-6A48C107-D179-4780-95E3-750309DC90D9Q35026759-A4DC1EDD-E5FC-419F-A8C0-0FED196B4570Q36174265-349145D9-00D3-436A-AADA-097BEA13B2ABQ36328417-EC6F3735-5DA8-4EFE-AFAF-F4BFFCB34DFBQ36964715-0B47B284-F370-41CB-B13B-C57EDCB06A09Q37176415-47DBAD92-0B54-44D6-AEB9-DDDB03A00E97Q37843827-8A02863E-D736-46D4-B019-6714331D71F7Q37852720-5E1F4A47-35C0-4B53-8CA8-548DB923E2E4Q37892906-52B49100-92C9-434A-B288-42DFC52F3C11Q38042707-798249FF-5FD4-420E-A7FC-C4FC15283824Q39400678-02ABAED2-A6EC-4A1C-8A21-BD7CEEFAC1BAQ40274687-C74DD992-FED0-4019-B088-41C20529E793Q43180371-ACB8576E-EEFE-4F74-830D-D58408CD6363Q44795024-D0ADA569-5E85-431C-9914-9E52B2F3146D
P2860
Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Tolvaptan administration does ...... ients with cardiac arrhythmias
@ast
Tolvaptan administration does ...... ients with cardiac arrhythmias
@en
Tolvaptan administration does ...... ients with cardiac arrhythmias
@nl
type
label
Tolvaptan administration does ...... ients with cardiac arrhythmias
@ast
Tolvaptan administration does ...... ients with cardiac arrhythmias
@en
Tolvaptan administration does ...... ients with cardiac arrhythmias
@nl
prefLabel
Tolvaptan administration does ...... ients with cardiac arrhythmias
@ast
Tolvaptan administration does ...... ients with cardiac arrhythmias
@en
Tolvaptan administration does ...... ients with cardiac arrhythmias
@nl
P2093
P2860
P1476
Tolvaptan administration does ...... ients with cardiac arrhythmias
@en
P2093
Cesare Orlandi
Jorge Lerman
Jorge Trongé
Kumara Sekar
Marcelo Víctor Elizari
N Alejandro Barbagelata
Steven Lee Bramer
Susan Elizabeth Shoaf
P2860
P304
P356
10.1177/107424840501000304
P407
P577
2005-09-01T00:00:00Z